Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company advancing therapies targeting C1q to address neuroinflammatory and autoimmune disorders. This page provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about Annexon’s pipeline candidates including ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy, and ANX1502 for systemic autoimmune conditions. Our curated news collection delivers verified press releases and analysis to support informed decision-making.
Key updates include clinical trial progress, scientific presentations, partnership announcements, and regulatory filings. All content is vetted for accuracy and relevance to complement inhibition therapies.
Bookmark this page for streamlined access to Annexon’s latest developments in targeting upstream complement pathways. Check regularly for authoritative updates on novel treatments for diseases with high unmet medical needs.
Annexon (ANNX) announced positive topline results from a real-world evidence study comparing ANX005 treatment to IVIg/PE for Guillain-Barré Syndrome (GBS). The study matched 79 ANX005-treated patients from Phase 3 trials with 79 real-world patients from the IGOS registry. Key findings showed ANX005 patients demonstrated:
- Over 10-point improvement in muscle strength by week 1 vs IVIg/PE
- Twice the likelihood of better health status on GBS-Disability Scale
- Lower mechanical ventilation needs (15 vs 32 patients)
- 12 fewer median days on ventilation and in ICU
The company plans to submit a U.S. Biologics License Application in first half of 2025. ANX005 is designed to block C1q and complement activity with a single dose, potentially offering the first FDA-approved treatment for GBS.
Annexon (NASDAQ: ANNX) announced presentations of ANX007 data from the Phase 2 ARCHER trial in geographic atrophy (GA) at the Floretina-ICOOR 2024 meeting in Florence, Italy. ANX007, a first-in-kind non-pegylated antigen-binding fragment, is designed to block C1q locally in the eye through intravitreal formulation.
The company will showcase multiple presentations focusing on vision protection and photoreceptor preservation in GA patients. The presentations will highlight the program's unique achievement in demonstrating significant vision protection in standard and low light conditions, along with preservation of photoreceptors in the fovea region. A pivotal Phase 3 ARCHER II trial is currently enrolling patients, with data expected in the second half of 2026.
Annexon (Nasdaq: ANNX) has granted stock options to seven new non-executive employees under its 2022 Employment Inducement Award Plan. The grants, approved on November 12, 2024, comply with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase 495,000 shares of common stock at an exercise price of $6.12 per share, matching the closing price on November 15, 2024. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and 1/48th monthly thereafter, contingent on continued employment.
Annexon reported Q3 2024 financial results and key milestones. The company expects topline Real-World Evidence data for ANX005 in Guillain-Barré Syndrome by year-end 2024, with BLA submission planned for H1 2025. The Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy continues enrollment with topline data expected H2 2026. Their oral C1s inhibitor ANX1502 study data in Cold Agglutinin Disease is expected in Q1 2025.
Financial highlights include cash position of $340.1 million as of September 30, 2024, providing runway into H2 2026. Q3 2024 net loss was $34.8 million ($0.25 per share), with R&D expenses at $30.1 million and G&A expenses at $9.3 million.
Annexon Biosciences (Nasdaq: ANNX) has announced its participation in the upcoming Jefferies London Healthcare Conference. Douglas Love, president and CEO, will deliver a presentation on Wednesday, November 20, 2024, at 10:30 a.m. GMT. The presentation will be accessible via live webcast in the 'Events & Presentations' section of the company's investor page. A recording will remain available on the Annexon website for 30 days after the event. The company specializes in developing therapies for neuroinflammatory diseases affecting the body, brain, and eye, focusing on upstream C1q.
Annexon presented new Phase 2 data for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD) at the American Academy of Ophthalmology 2024 meeting. The study showed enhanced vision protection and greater preservation of central photoreceptor cells in patients with less advanced disease. Key findings include:
- 0% of ANX007 monthly-treated patients with less advanced disease lost 15 letters vs. 17% of sham patients
- 6% of ANX007 monthly-treated overall patients lost 15 letters vs. 21% of sham overall patients
- 61% decrease in EZ loss between ANX007 and sham in patients with <80% EZ loss at baseline
- 48% decrease in EZ loss between ANX007 and sham in patients with <98% EZ loss at baseline
These results highlight ANX007's potential for earlier intervention in dry AMD and GA. Pivotal Phase 3 ARCHER II data is expected in the second half of 2026.
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing therapies for neuroinflammatory diseases, has announced the granting of inducement awards to seven new non-executive employees. These equity awards were approved on October 10, 2024, in compliance with Nasdaq Listing Rule 5635(c)(4).
The awards consist of options to purchase a total of 643,500 shares of Annexon common stock. The options have a ten-year term and an exercise price of $7.45 per share, which was the closing price of Annexon's stock on October 15, 2024. The options will vest over 4 years, with 25% vesting on the first anniversary of the grant date and an additional 1/48th vesting monthly thereafter, subject to continued employment.
Annexon, Inc. (Nasdaq: ANNX) will present new analyses of ANX007 from the completed Phase 2 ARCHER trial in geographic atrophy (GA) at the American Academy of Ophthalmology (AAO) 2024 annual meeting and the Eyecelerator conference at AAO. ANX007, a first-in-kind, non-pegylated antigen-binding fragment (Fab), is designed to block C1q locally in the eye with an intravitreal formulation.
Key highlights include:
- ANX007 demonstrated significant vision protection in standard and low light conditions
- Significant photoreceptor preservation was observed in the fovea region critical for visual acuity
- Phase 3 data from the ongoing ARCHER II pivotal program is expected in the second half of 2026
Presentations will be made by Dr. Rahul N. Khurana and Douglas Love at the respective events in Chicago, Illinois.
Annexon (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel complement therapies for neuroinflammatory diseases, has granted stock options to six new non-executive employees under its 2022 Employment Inducement Award Plan. The equity awards, approved on September 13, 2024, comply with Nasdaq Listing Rule 5635(c)(4). In total, the new employees received options to purchase 1,015,000 shares of Annexon common stock. These options have a ten-year term and an exercise price of $7.20 per share, matching the closing price of Annexon's stock on the grant date. The options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly, subject to continued employment.
Annexon (Nasdaq: ANNX) will present analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA) at two major ophthalmology conferences. ANX007, a novel C1q-blocking Fab, demonstrated significant vision protection in standard and low light conditions, and preservation of photoreceptors in the fovea region. The company has initiated the Phase 3 ARCHER II pivotal trial, with data expected in the second half of 2026. Presentations will highlight ANX007's potential to be the first treatment to protect vision in GA, focusing on its mechanism of action and clinical results from the ARCHER trial.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
